Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Oct 28 - Nov 2
The ChEMBL drug registry records tirzepatide at maximum phase 4 (approved), first approval 2022, parenteral, with a first-in-class GIP-agonist designation and a boxed-warning flag
Well cover its mechanism of action, scientific research on how well it works and how safe it is, recommended dosages, things to think about when buying, and answers to common questions
Continue Reading To learn more about research peptides and laboratory best practices, explore our related guides: Research Peptide Quality Control: HPLC, LC-MS & COAs Explained How to Store Research Peptides Correctly GHK-Cu Research Guide These resources provide additional information on peptide quality, storage, supplier evaluation, and research-focused procurement practices to help laboratories make well-informed purchasing decisions.
The Future of Peptides and Drug Testing As research into peptides like BPC-157, IGF-1 LR3, Ipamorelin, and HCG continues to evolve, the methods for detecting these substances will also improve
